Successfully Addressing Bladder Disease with Unique Intravesical Therapies

TRIGONE WAS FOUNDED WITH THE GOAL OF ADDRESSING UNMET MEDICAL NEEDS RELATED TO BLADDER DISEASE

To achieve our goal, our experienced team leverages their deep understanding of bladder physiology to develop drug delivery systems for effective relief of bladder disorders.

glow-shape

Trigone proprietary intravesical treatments are designed to address complex bladder disease where other approaches aren’t providing the desired results.

Our approach enables the generation of highly targeted treatments which aims to achieve optimal durable therapeutic effect in the bladder, restoring the patents’ quality of life.

Our clinical pipeline features effective and safe therapies exerting prolonged drug exposure to the target organ, primarily required for good clinical outcomes of bladder cancer or bladder pain syndrome.

Our Team

Dan Touitou
CEO
More than two decades of experience in the pharmaceutical industry with a track record in managing young pharma companies partnering with major international companies including J&J, Pfizer, Galderma, and Syneron.
Nadav Malchi
CTO
More than 22 years’ experience in the pharma industry, managing worldwide clinical and preclinical trials in urology. Formerly COO of Urogen.
Avigdor Gordon
CRA
Expert in leading regulatory strategy, non-clinical and clinical affairs, with over 30 years of supporting development, approvals, and marketing activities, including at Urogen.

Contact US

Interested to get in touch with us?

Fill out the form bellow

Trigone Pharma Ltd. © 2024 by Trigone Pharma
Site by IMAGINET

Accessibility Toolbar